Inflammatory bowel disease-associated colorectal cancer: translational risks from mechanisms to medicines

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

The cumulative impact of chronic inflammation in patients with inflammatory bowel diseases predisposes to the development of inflammatory bowel disease-associated colorectal cancer (IBD-CRC). Inflammation can induce mutagenesis and the relapsing-remitting nature of this inflammation, together with epithelial regeneration, may exert selective pressure accelerating carcinogenesis. The molecular pathogenesis of IBD-CRC, termed the ‘inflammation-dysplasia-carcinoma’ sequence, is well described. However, the immunopathogenesis of IBD-CRC is less well understood. The impact of novel immunosuppressive therapies, which aim to achieve deep remission, is mostly unknown. Therefore, this timely review summarises the clinical context of IBD-CRC, outlines the molecular and immunological basis of disease pathogenesis and considers the impact of novel biologic therapies.
Original languageEnglish
JournalJournal of Crohn's and Colitis
Early online date10 Jun 2021
DOIs
Publication statusE-pub ahead of print - 10 Jun 2021

Keywords / Materials (for Non-textual outputs)

  • colitis-associated cancer
  • cancer
  • biological ageing

Fingerprint

Dive into the research topics of 'Inflammatory bowel disease-associated colorectal cancer: translational risks from mechanisms to medicines'. Together they form a unique fingerprint.

Cite this